Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics presented encouraging clinical data on AlloNK, their off-the-shelf NK cell therapy combined with rituximab, showing deep B-cell depletion and meaningful clinical responses in refractory rheumatoid arthritis (RA) and other autoimmune diseases at EULAR 2026. The FDA granted RMAT designation to AlloNK for refractory RA, supporti…